ABILIFY

Compare ABILIFY  to:
Compare
Compare

Generic Name for ABILIFY

Aripiprazole 2mg, 5mg, 10mg, 15mg, 20mg, 30mg; tabs.

Legal Classification:

Rx

Manufacturer of ABILIFY

BMS/Otsuka Partnership

Indications for ABILIFY

Acute and maintenance treatment of manic or mixed episodes in bipolar disorder as monotherapy; or as an adjunct to lithium or valproate. Adjunct to antidepressants for major depressive disorder. Irritability associated with autistic disorder.

Adult dose for ABILIFY

Tabs and soln may be interchanged on a mg–to–mg basis up to 25mg; 30mg as tablet is equivalent to 25mg oral soln. Discmelt: Dissolve on tongue; take without liquids. Bipolar disorder: initially 15mg once daily; may increase to max 30mg/day; maintenance: 15mg/day or 30mg/day (see literature for duration of therapy). Adjunct to major depressive disorder: initially 2–5mg/day; may adjust by 5mg/day increments at intervals of ≥1 week; usual range: 2–15mg/day. Reduce aripiprazole dose by at least ½ with CYP3A4 inhibitors or CYP2D6 inhibitors. Double aripiprazole dose (max 30mg/day) with CYP3A4 inducers. Adjust dose to normal range when these drugs are withdrawn.

Children's dosing for ABILIFY

<10yrs: not recommended. 10–17yrs: Bipolar disorder: initially 2mg/day, then increase to 5mg/day after 2 days, then increase to target dose of 10mg/day after 2 days. Subsequent dose increases may be adjusted by increments of 5mg/day; max 30mg/day. Maintenance: continue at lowest dose to maintain remission; see literature. Irritability w. autistic disorder: 6–17yrs: initially 2mg/day, then increase to 5mg/day; adjust dose by 5mg/day at ≥1 week intervals; usual range 5–15mg/day.

Also:

Precautions for ABILIFY

Cardio- or cerebrovascular disease. Risk of hypotension, aspiration pneumonia, seizures, or diabetes (do baseline fasting blood sugar). Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Exposure to extreme heat. Dehydration. Reevaluate periodically. Monitor for hyperglycemia. Exclude neuroleptic malignant syndrome if fever occurs. Suicidal tendencies. Write ℞ for smallest practical amount. Elderly (not for dementia-related psychosis). Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for ABILIFY

Avoid alcohol. Caution with other centrally-acting drugs. Potentiates antihypertensives. Levels may be reduced by CYP3A4 inducers (eg, carbamazepine). Levels may be increased by CYP3A4 inhibitors (eg, ketoconazole) or CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). Caution with drugs that interfere with temperature regulation (eg, anticholinergics).

Adverse Reactions for ABILIFY

Headache, anxiety, insomnia, GI upset, somnolence, fatigue, akathisia, orthostatic hypotension, asthenia, blurred vision, tremor, pyrexia, salivary hypersecretion, neuroleptic malignant syndrome, tardive dyskinesia, weight gain, others. Inj: local reactions.

How is ABILIFY supplied?

Tabs 2mg—30
5mg, 10mg, 15mg, 20mg, 30mg—30, 100
Oral soln (w. dosing cup)—150mL
Discmelt—30
Single use vials—1

Related Disease:

Bipolar disorder
Depression
Irritability
Mania

Related Resources

Oleptro approved for major depressive disorder (MDD)

February 03, 2010

The FDA has approved Oleptro (trazodone HCl extended-release tablets, from Labopharm), a once-daily formulation of trazodone, for the treatment of major depressive disorder (MDD) in adults.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Seroquel XR approved for adjunctive treatment of major depressive disorder (MDD)

December 07, 2009

Seroquel XR (quetiapine fumarate extended-release tablets, from AstraZeneca) has been approved by the FDA as adjunctive treatment to antidepressants in adults with major depressive disorder (MDD).

Zyprexa approved for schizophrenia and bipolar I disorder in adolescents

December 07, 2009

The FDA has approved Zyprexa (olanzapine, from Lilly) tablets for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents 13-17 years of age.

FDA warns of birth defects with valproate sodium, valproic acid, and divalproex sodium

December 03, 2009

The FDA has notified healthcare professionals and patients about the increased risk of neural tube defects and other major birth defects (eg, craniofacial defects and cardiovascular malformations) in babies exposed to valproate sodium and related products (valproic acid and divalproex sodium) during pregnancy.